Staging preview: health content pending qualified review
D2C Peptides

Research goal

Semaglutide and blood sugar

Semaglutide for diabetes is FDA approved as Ozempic injection and as Rybelsus and Ozempic tablets, to improve blood sugar control in adults with type 2 diabetes.12 In a 30-week Ozempic trial, HbA1c fell 1.4 to 1.6 points vs 0.1 on placebo.3 These are group averages, and whether it suits a patient is a prescriber's decision.

This page summarizes published sources for information only. It is not medical advice and does not tell anyone to use a product. Questions about your own health belong with a licensed clinician. For questions about an order or a product, contact us.

What sources report

How it acts on blood sugar

Semaglutide stimulates insulin release and lowers glucagon release in a glucose-dependent way, and it causes a minor delay in stomach emptying soon after a meal; together these lower blood sugar.14 Appetite effects and the molecule's design are covered on What is Semaglutide?.

HbA1c and weight on the Ozempic label

Trial on the Ozempic label3 HbA1c change Body weight change
30 weeks, semaglutide 0.5 mg weekly -1.4 points -3.8 kg
30 weeks, semaglutide 1 mg weekly -1.6 points -4.7 kg
30 weeks, placebo -0.1 points -1.2 kg
40 weeks, semaglutide 1 mg weekly -1.9 points -5.6 kg
40 weeks, semaglutide 2 mg weekly -2.1 points -6.4 kg

The 30-week trial tested semaglutide alone (monotherapy) in type 2 diabetes. In the 40-week trial, the weight difference between 2 mg and 1 mg was not statistically significant.3

Heart outcomes in type 2 diabetes

SUSTAIN-6 followed 3,297 people with type 2 diabetes for 104 weeks on semaglutide 0.5 or 1.0 mg weekly or placebo.16 The primary cardiovascular outcome occurred in 6.6% vs 8.9% (hazard ratio 0.74), and nonfatal stroke in 1.6% vs 2.7%.16 Retinopathy complications were more frequent with semaglutide (hazard ratio 1.76).16

Kidney outcomes

FLOW gave semaglutide 1.0 mg weekly or placebo to 3,533 people with type 2 diabetes and chronic kidney disease.15 It stopped early after a planned interim analysis, at a median follow-up of 3.4 years, with a 24% lower risk of the primary kidney outcome on semaglutide (hazard ratio 0.76).15

Tablets for type 2 diabetes

Semaglutide for diabetes also comes as once-daily tablets: Rybelsus (3, 7 and 14 mg) and Ozempic tablets (1.5, 4 and 9 mg).9 Their first doses, 3 mg and 1.5 mg, are starting doses that the labels say are not effective for glucose control.217 The most common side effects on the shared tablet label are nausea, abdominal pain, diarrhea, decreased appetite, vomiting and constipation.17

Weight change in type 2 diabetes

In the Wegovy label's two 72-week studies, adults with obesity and type 2 diabetes lost less weight than adults with obesity but without type 2 diabetes in the other study: -10.4% vs -15.5% on 2.4 mg weekly, and -13.2% vs -18.8% on 7.2 mg.18 The full weight data are on Semaglutide and weight loss.

Limits of this evidence

All of these figures are group averages from trials of semaglutide medicines.316 The sources used here give no HbA1c results for the tablets and do not address type 1 diabetes, so this page covers neither. None of them concerns research-labeled semaglutide; FDA says unapproved versions of GLP-1 drugs do not undergo its review for safety, effectiveness and quality.19

What the label says

Ozempic injection is approved for adults with type 2 diabetes for three uses.1

  • Blood sugar control, alongside diet and exercise.1
  • Lowering the risk of major cardiovascular events (cardiovascular death, nonfatal heart attack or nonfatal stroke) in those with established cardiovascular disease.1
  • Lowering the risk of sustained kidney function decline, end-stage kidney disease and cardiovascular death in those with chronic kidney disease.1

Rybelsus and Ozempic tablets share one label.2 It covers blood sugar control in adults with type 2 diabetes, and lowering the risk of major cardiovascular events in high-risk adults with type 2 diabetes.2

The prescriber sets the dose. Ozempic injection starts at 0.25 mg weekly for 4 weeks, then 0.5 mg, with increases to 1 mg and then 2 mg, the maximum, if more glucose control is needed; the maintenance dose for chronic kidney disease is 1 mg.8 Injection and tablet schedules side by side are on Semaglutide dosage.

Label warnings that matter most in diabetes:

  • Low blood sugar: combining semaglutide with insulin or an insulin secretagogue raises the risk, including severe low blood sugar.12
  • Diabetic eye disease: retinopathy complications occurred in 3.0% vs 1.8% in a 2-year Ozempic trial, and rapid improvement in blood sugar can temporarily worsen diabetic retinopathy.20
  • Severe gastroparesis: Ozempic is not recommended.20
  • Boxed warning: thyroid C-cell tumors in rodents, with human relevance unknown.21

FDA has also found counterfeit Ozempic in the US drug supply chain, and it advises getting Ozempic only with a valid prescription through state-licensed pharmacies.22 The complete list of side effects is on Semaglutide side effects. None of this covers research-labeled semaglutide, which no approved application covers and which FDA treats as an unapproved new drug when it is intended for people.10

More on this goal: Peptides and blood sugar, Ozempic and blood sugar, Rybelsus and blood sugar, Tirzepatide and blood sugar and Semaglutide and weight loss.

Read next

More goal pages

Frequently asked questions

What happens if you take semaglutide without diabetes?

Wegovy's weight and heart indications do not require diabetes, and the SELECT trial enrolled 17,604 adults with heart disease and overweight or obesity but no history of diabetes.45 The Wegovy label lists low blood sugar as a common side effect only in patients with type 2 diabetes; digestive side effects are the most common for everyone.6 Use without diabetes is still prescription only and set by a prescriber.7

Is Ozempic the same as semaglutide?

Ozempic is one brand of semaglutide: an FDA-approved prescription injection (0.25 to 2 mg weekly) and tablet for adults with type 2 diabetes.189 Wegovy and Rybelsus contain the same molecule at different doses and for different uses.49 A research vial labeled semaglutide is not Ozempic; FDA treats research-labeled semaglutide sold for human use as an unapproved new drug.1011 See Ozempic vs Semaglutide.

Does semaglutide cause low blood sugar?

It can. In a Wegovy trial in people with type 2 diabetes, clinically significant low blood sugar (below 54 mg/dL) occurred in 6.2% vs 2.5% on placebo.13 The labels warn that the risk rises, including severe episodes, when semaglutide is used with insulin or an insulin secretagogue.12 The Ozempic label describes its effects on insulin and glucagon as glucose-dependent.14

Does semaglutide protect the kidneys in diabetes?

In the FLOW trial of 3,533 people with type 2 diabetes and chronic kidney disease, semaglutide 1.0 mg weekly lowered the risk of the main kidney outcome by 24% compared with placebo.15 Median follow-up was 3.4 years.15 The Ozempic label now includes lowering the risk of sustained kidney function decline, end-stage kidney disease and cardiovascular death in adults with type 2 diabetes and chronic kidney disease.1

How much does semaglutide lower A1C?

On the Ozempic label, a 30-week trial of semaglutide alone lowered HbA1c by 1.4 points at 0.5 mg and 1.6 points at 1 mg weekly, vs 0.1 points on placebo.3 In a 40-week trial, 2 mg lowered HbA1c by 2.1 points vs 1.9 points with 1 mg.3 Individual results vary, and the dose is set by a prescriber.8

Written by D2C Peptides Editorial Team.

Pending qualified review.

Updated .

Sources

  1. OZEMPIC (semaglutide) injection prescribing information, Indications and Usage; DailyMed listing. DailyMed, U.S. National Library of Medicine (Novo Nordisk label, revised 5/2026), 2026.
  2. OZEMPIC (semaglutide) tablets and RYBELSUS (semaglutide) tablets prescribing information, Indications and Usage. DailyMed, U.S. National Library of Medicine (Novo Nordisk label, revised 1/2026), 2026.
  3. Same source as 1: section 14 Clinical Studies.
  4. WEGOVY (semaglutide) injection and tablets prescribing information, section 1 Indications and Usage. DailyMed, U.S. National Library of Medicine (Novo Nordisk label, revised 6/2026), 2026.
  5. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT; Lincoff et al.), PubMed abstract PMID 37952131. New England Journal of Medicine (abstract via NLM PubMed E-utilities), 2023.
  6. Same source as 4: WEGOVY (semaglutide) prescribing information, Highlights: most common adverse reactions; section 6.1 Table 3.
  7. Drugs@FDA: WEGOVY, WEGOVY FLEXTOUCH, WEGOVY HD, NDA 215256. U.S. Food and Drug Administration.
  8. Same source as 1: section 2 Dosage and Administration.
  9. Drugs@FDA: OZEMPIC tablets and RYBELSUS, NDA 213051. U.S. Food and Drug Administration.
  10. Warning Letter: Xcel Research LLC (MARCS-CMS 694608), December 10, 2024. U.S. Food and Drug Administration, 2024.
  11. Warning Letter: USApeptide.com (MARCS-CMS 696885), February 26, 2025. U.S. Food and Drug Administration, 2025.
  12. Same source as 1: Warnings (pancreatitis, hypoglycemia) and Use in Specific Populations.
  13. Same source as 4: WEGOVY (semaglutide) prescribing information, section 5 Warnings and Precautions (gallbladder, heart rate).
  14. Same source as 1: section 12.1 Mechanism of Action.
  15. Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes (FLOW; Perkovic et al.), PubMed abstract PMID 38785209. New England Journal of Medicine (abstract via NLM PubMed E-utilities), 2024.
  16. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN-6; Marso et al.), PubMed abstract PMID 27633186. New England Journal of Medicine (abstract via NLM PubMed E-utilities), 2016.
  17. Same source as 2: Ozempic tablet dosing and adverse reactions.
  18. Same source as 4: WEGOVY (semaglutide) prescribing information, section 14 Clinical Studies.
  19. FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss (compounded drugs). U.S. Food and Drug Administration (content current as of 10/01/2026), 2026.
  20. Same source as 1: Warnings and Precautions (diabetic retinopathy, gastrointestinal).
  21. Same source as 1: Boxed Warning.
  22. FDA warns consumers not to use counterfeit Ozempic (semaglutide) found in U.S. drug supply chain. U.S. Food and Drug Administration (content current as of 12/05/2025), 2025.